Pulse Biosciences (NASDAQ:PLSE) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Pulse Biosciences (NASDAQ:PLSE) from a sell rating to a hold rating in a report published on Sunday morning,Wall Street Zen reports.

A number of other equities analysts also recently issued reports on the stock. Canaccord Genuity Group increased their price objective on shares of Pulse Biosciences from $32.00 to $43.00 and gave the company a “buy” rating in a research note on Monday, August 10th. Needham & Company LLC began coverage on shares of Pulse Biosciences in a research note on Monday, August 17th. They issued a “buy” rating and a $58.00 price objective for the company. Oppenheimer restated an “outperform” rating on shares of Pulse Biosciences in a report on Tuesday, July 28th. Mizuho set a $45.00 target price on Pulse Biosciences in a research report on Monday, August 10th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pulse Biosciences in a research report on Friday, July 17th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $45.25.

Pulse Biosciences Price Performance

PLSE stock opened at $48.79 on Friday. Pulse Biosciences has a 1-year low of $12.56 and a 1-year high of $55.37. The business has a 50-day moving average price of $38.88 and a 200 day moving average price of $28.41. The company has a market capitalization of $3.38 billion, a P/E ratio of -41.35 and a beta of 1.63.

Pulse Biosciences (NASDAQ:PLSE) last issued its earnings results on Thursday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.07). The business had revenue of $0.43 million for the quarter, compared to the consensus estimate of $0.53 million. Pulse Biosciences had a negative return on equity of 94.42% and a negative net margin of 6,755.78%. On average, analysts anticipate that Pulse Biosciences will post -1.29 earnings per share for the current fiscal year.

Insider Buying and Selling at Pulse Biosciences

In other news, COO Liane Teplitsky acquired 1,001 shares of the business’s stock in a transaction dated Tuesday, September 1st. The shares were purchased at an average price of $49.95 per share, with a total value of $49,999.95. Following the transaction, the chief operating officer directly owned 4,095 shares in the company, valued at approximately $204,545.25. This represents a 32.35% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last quarter, insiders have bought 4,095 shares of company stock valued at $199,931. 74.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Pulse Biosciences

Institutional investors have recently bought and sold shares of the company. California State Teachers Retirement System grew its holdings in Pulse Biosciences by 2,600.0% in the second quarter. California State Teachers Retirement System now owns 567,883 shares of the company’s stock worth $15,747,000 after purchasing an additional 546,850 shares during the last quarter. Formula Growth Ltd. purchased a new stake in shares of Pulse Biosciences during the 2nd quarter valued at $832,000. Panoramic Capital LLC acquired a new stake in shares of Pulse Biosciences in the 2nd quarter worth $2,719,000. Bank of America Corp DE acquired a new stake in shares of Pulse Biosciences in the 2nd quarter worth $40,115,000. Finally, Jupiter Topco LLC acquired a new stake in shares of Pulse Biosciences in the 2nd quarter worth $241,000. 76.95% of the stock is currently owned by institutional investors and hedge funds.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.